Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3245508 | 0.74 | ALDH1A1 (0.41) | NPSR1ALDH1A1ALOX15HSP90AA1KMT2A | |
| SCHEMBL28819096 | 0.73 | — | — | |
| SCHEMBL104821 | 0.72 | ALDH1A1 (0.42) | NPSR1ALDH1A1ALOX15HSP90AA1KMT2A | |
| SCHEMBL3664780 | 0.70 | NPSR1 (0.46) | NPSR1ALDH1A1ALOX15KMT2AHTT | |
| SCHEMBL3241706 | 0.69 | ESR1 (0.46) | NPSR1ALDH1A1HSP90AA1KMT2AHTT | |
| SCHEMBL7668425 | 0.69 | NPSR1 (0.39) | NPSR1ALDH1A1ALOX15HSP90AA1KMT2A | |
| SCHEMBL3486864 | 0.69 | NPSR1 (0.39) | NPSR1ALDH1A1ALOX15HSP90AA1KMT2A | |
| SCHEMBL3239982 | 0.69 | NPSR1 (0.44) | NPSR1ALDH1A1KMT2AHTTMEN1 | |
| SCHEMBL8394594 | 0.68 | ALDH1A1 (0.39) | NPSR1ALDH1A1ALOX15HSP90AA1KMT2A | |
| SCHEMBL2015505 | 0.68 | ALDH1A1 (0.39) | NPSR1ALDH1A1ALOX15HSP90AA1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014200882-A1 | PDE10a INHIBITORS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-18 | — | — | WO | claimed |
| CN-102702194-A | Anti-viral compounds | ABBOTT LAB | 2012-10-03 | — | — | CN | claimed |
| US-20100256139-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2010-10-07 | — | — | US | claimed |
| EP-1979349-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2010-07-28 | — | — | EP | claimed |
| EP-1979349-A2 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-10-15 | — | — | EP | claimed |
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | claimed |
| WO-2007076035-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-05 | — | — | WO | claimed |
| US-6218379-B1 | Tricyclic carbacephems | HOFFMANN-LA ROCHE INC. | 2001-04-17 | — | — | US | claimed |
| EP-0912574-A1 | BETA-LACTAMS | F. HOFFMANN-LA ROCHE AG (CH) | 1999-05-06 | — | — | EP | claimed |
| EP-0879223-A1 | AROMATIC POLYCYCLIC RETINOID-TYPE DERIVATIVES, METHOD FOR PREPARING SAME, AND USE THEREOF FOR MAKING PHARMACEUTICAL AND COSMETIC COMPOSITIONS | Centre Europeen de Bioprospective -CEB (FR) | 1998-11-25 | — | — | EP | claimed |
| WO-1997026237-A1 | AROMATIC POLYCYCLIC RETINOID-TYPE DERIVATIVES, METHOD FOR PREPARING SAME, AND USE THEREOF FOR MAKING PHARMACEUTICAL AND COSMETIC COMPOSITIONS | CENTRE EUROPEEN DE BIOPROSPECTIVE - CEB (FR) | 1997-07-24 | — | — | WO | claimed |
| US-5563129-A | Hydroquinone derivatives and intermediates for production thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-10-08 | — | — | US | claimed |
| US-5494666-A | BETA-LACTAMASE INHIBITORS, ANTIBACTERIALS | HOFFMANN-LA ROCHE INC. (US) | 1996-02-27 | — | — | US | claimed |
| US-5464617-A | 1H-2,6a-diazacyclobut(cd)indene-6-carboxylic acid derivatives, antibiotics | HOFFMANN-LA ROCHE INC. (US) | 1995-11-07 | — | — | US | claimed |
| EP-0671401-A1 | Beta lactames | F. HOFFMANN-LA ROCHE AG (CH) | 1995-09-13 | — | — | EP | claimed |
| US-5354913-A | Chemical intermediates for drugs or drugs as thromboxane, prostaglandin antagonist, lipoxygenase enzyme inhibitor, antioxidants | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-10-11 | — | — | US | claimed |
| US-5304658-A | Quinone derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-04-19 | — | — | US | claimed |
| EP-0234729-B1 | QUINONE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1991-12-27 | — | — | EP | claimed |
| CN-87100723-A | Quinone derivative, their preparation and use | — | 1987-09-16 | — | — | CN | claimed |
| EP-0234729-A2 | Quinone derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1987-09-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | NPSR1 3949/4885ALDH1A1 2723/4885ALOX15 1858/4885 |
| US-20100256139-A1 | Anti-Viral Compounds | HAVCR2, MAVS, EIF2AK2 | NPSR1 3949/4885ALDH1A1 2723/4885ALOX15 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.